BRPI0017528A2 - uso de uma composição contendo sal de cetotifeno - Google Patents

uso de uma composição contendo sal de cetotifeno

Info

Publication number
BRPI0017528A2
BRPI0017528A2 BRPI0017528A BRPI0017528A2 BR PI0017528 A2 BRPI0017528 A2 BR PI0017528A2 BR PI0017528 A BRPI0017528 A BR PI0017528A BR PI0017528 A2 BRPI0017528 A2 BR PI0017528A2
Authority
BR
Brazil
Prior art keywords
composition containing
ketotifen salt
containing ketotifen
salt
composition
Prior art date
Application number
Other languages
English (en)
Inventor
Andrea Fetz
Gyorgy Lajos Kis
Marcia Johanna Adam
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0017528A2 publication Critical patent/BRPI0017528A2/pt
Publication of BRPI0017528B1 publication Critical patent/BRPI0017528B1/pt
Publication of BRPI0017528B8 publication Critical patent/BRPI0017528B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0017528A 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno BRPI0017528B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99114508.7 1999-07-23
EP99114508 1999-07-23
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (3)

Publication Number Publication Date
BRPI0017528A2 true BRPI0017528A2 (pt) 2010-01-19
BRPI0017528B1 BRPI0017528B1 (pt) 2017-06-13
BRPI0017528B8 BRPI0017528B8 (pt) 2021-05-25

Family

ID=8238654

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0017528A BRPI0017528B8 (pt) 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica

Country Status (20)

Country Link
US (2) US6777429B1 (pt)
EP (1) EP1198223A2 (pt)
JP (1) JP2003505419A (pt)
KR (1) KR20020012261A (pt)
CN (1) CN1358086A (pt)
BR (2) BRPI0017528B8 (pt)
CA (1) CA2377024A1 (pt)
CZ (1) CZ300614B6 (pt)
EE (1) EE05439B1 (pt)
HK (1) HK1046631A1 (pt)
HU (1) HU230738B1 (pt)
IL (1) IL146973A0 (pt)
MX (1) MXPA02000849A (pt)
NO (1) NO331228B1 (pt)
NZ (1) NZ516108A (pt)
PL (1) PL202496B1 (pt)
RU (1) RU2248789C2 (pt)
UA (1) UA74788C2 (pt)
WO (1) WO2001007049A2 (pt)
ZA (1) ZA200200425B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
JP4629578B2 (ja) * 2003-01-22 2011-02-09 ニチバン株式会社 眼疾患治療用経皮吸収型製剤
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
WO2006047418A1 (en) * 2004-10-25 2006-05-04 Alimera Sciences, Inc. Ophthalmic compositions and methods of using the same
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
ES2624960T3 (es) 2006-09-29 2017-07-18 Johnson & Johnson Vision Care, Inc. Método de fabricación de dispositivos oftálmicos usados en el tratamiento de alergias oculares
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009045291A2 (en) 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
KR20020012261A (ko) 2002-02-15
WO2001007049A2 (en) 2001-02-01
IL146973A0 (en) 2002-08-14
JP2003505419A (ja) 2003-02-12
US20020183359A1 (en) 2002-12-05
PL202496B1 (pl) 2009-06-30
CN1358086A (zh) 2002-07-10
CZ2002243A3 (cs) 2002-04-17
HUP0202243A3 (en) 2006-03-28
MXPA02000849A (es) 2002-07-30
BRPI0017528B1 (pt) 2017-06-13
RU2248789C2 (ru) 2005-03-27
HK1046631A1 (zh) 2003-01-24
NO20020319L (no) 2002-01-21
NO331228B1 (no) 2011-11-07
HUP0202243A2 (hu) 2002-12-28
BR0012696A (pt) 2002-04-09
EE05439B1 (et) 2011-08-15
WO2001007049A3 (en) 2001-03-29
US6777429B1 (en) 2004-08-17
EP1198223A2 (en) 2002-04-24
EE200200040A (et) 2003-04-15
CA2377024A1 (en) 2001-02-01
HU230738B1 (hu) 2018-01-29
NZ516108A (en) 2004-04-30
PL352382A1 (en) 2003-08-25
US6774137B2 (en) 2004-08-10
ZA200200425B (en) 2002-10-30
NO20020319D0 (no) 2002-01-21
UA74788C2 (en) 2006-02-15
CZ300614B6 (cs) 2009-07-01
BRPI0017528B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0017528A2 (pt) uso de uma composição contendo sal de cetotifeno
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
DE69920009D1 (de) Isothiazole derivate verwendbar als antikrebsmittel
ATE270089T1 (de) Kalziumsalze enthaltende schweisshemmende zusammensetzungen
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
DE69913233D1 (de) Kosmetische zusammensetzung
FI991485A0 (fi) Uusi farmaseuttinen koostumus
IS6120A (is) Lyfjablanda
ID20233A (id) Komposisi oral
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ATE326939T1 (de) Kosmetische zusammensetzung
ID29021A (id) Komposisi galantamina pelepasan terkontrol
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
DE60033021D1 (de) Strukturierte kosmetische zusammensetzungen
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
DE60031954D1 (de) Lippenstiftzusammensetzung
DE60036505D1 (de) Kosmetische Zubereitung enthaltend Titan-Kieselerde-Komplex
NO20021115L (no) Ny sammensetning
ID29262A (id) Komposisi farmasi
DE60011184D1 (de) Kosmetische Flüssigkristall Zusammensetzung
DE60043058D1 (de) Dentalwerkstoffe
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE69935411D1 (de) Zweikomponenten zahnpastazusammensetzung gegen zahnbelag
DE60037014D1 (de) Kosmetische zusammensetzungen enthaltend polysaccharid-sterol-derivate
DE60111988D1 (de) Kosmetische Zusammensetzung

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/07/2020